Literature DB >> 29049502

Benefits of Direct-Acting Antivirals for Hepatitis C.

Anna S Lok1, Raymond T Chung1, Hugo E Vargas1, Arthur Y Kim1, Susanna Naggie1, William G Powderly1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29049502     DOI： 10.7326/M17-1876

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  5 in total

1.  A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.

Authors:  B L Norton; A H Litwin
Journal:  Clin Infect Dis       Date:  2020-05-23       Impact factor: 9.079

2.  Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.

Authors:  Matthew J Akiyama; Brianna L Norton; Julia H Arnsten; Linda Agyemang; Moonseong Heo; Alain H Litwin
Journal:  Ann Intern Med       Date:  2019-04-09       Impact factor: 25.391

3.  Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.

Authors:  Aung H Bwa; Gayatri Nangia; Si T S Win; Soe T Maung; Khin A W Han; Su S Htar; Lei Y Wine; Wint W Ko; Moe P Oo; Naomi K T Hlaing; Julia Palecki; Bao L Loza; Khin M Win; Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2018-12-19

4.  Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.

Authors:  Charitha Gowda; Vincent Lo Re
Journal:  Curr Hepatol Rep       Date:  2018-03-24

5.  Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.

Authors:  Charitha Gowda; Stephen Lott; Matthew Grigorian; Dena M Carbonari; M Elle Saine; Stacey Trooskin; Jason A Roy; Jay R Kostman; Paul Urick; Vincent Lo Re
Journal:  Open Forum Infect Dis       Date:  2018-06-07       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.